Drug Trial Radar · NCT07348055
A Study of GR1803 in Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Jun 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Conditions
- Systemic Lupus Erthematosus
- Auto Immune Disease
Interventions
GR1803 injectionBiological
step-up dosing, Dose and frequency according to the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of adverse eventTime frame: 52 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.